{
    "clinical_study": {
        "@rank": "57098", 
        "arm_group": [
            {
                "arm_group_label": "Group1", 
                "arm_group_type": "Experimental", 
                "description": "PartA:CIM331 Part B:CIM331"
            }, 
            {
                "arm_group_label": "Group2", 
                "arm_group_type": "Experimental", 
                "description": "PartA:CIM331 Part B:CIM331"
            }, 
            {
                "arm_group_label": "Group3", 
                "arm_group_type": "Experimental", 
                "description": "PartA:CIM331 Part B:CIM331"
            }, 
            {
                "arm_group_label": "Group4", 
                "arm_group_type": "Experimental", 
                "description": "PartA:CIM331 Part B:CIM331"
            }, 
            {
                "arm_group_label": "Group5", 
                "arm_group_type": "Experimental", 
                "description": "PartA:Placebo Part B:CIM331"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic\n      dermatitis patients who are inadequately controlled by or intolerant to topical therapy"
        }, 
        "brief_title": "A Phase 2 Study of CIM331 for Atopic Dermatitis Patients", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u226518 and \u226465 years of age at the time of consent.\n\n          -  Patients with Atopic Dermatitis\n\n          -  Pruritus visual analogue scale (VAS) \u226550 mm at the screening and baseline visit\n\n          -  Eczema Area and Severity Index (EASI) \u226510 at the screening and baseline visit\n\n          -  static Investigator's Global Assessment (sIGA) score \u22653 at the baseline visit\n\n        Exclusion Criteria:\n\n          -  Serological evidence of hepatitis B virus or hepatitis C virus infection\n\n          -  Known human immunodeficiency virus infection\n\n          -  Ongoing treatment with specific or non-specific hyposensitization therapy for AD\n\n          -  Treatment with mild or moderately potent topical corticosteroids (TCS) within 1 week\n             prior to randomization\n\n          -  History of infection including skin infection requiring treatment with oral or\n             intravenous (IV) antibiotics, antivirals, or antifungals within 1 week prior to\n             randomization.\n\n          -  Evidence of tuberculosis (TB) infection as defined by a positive purified protein\n             derivative (PPD) and/or positive interferon-gamma release assay.\n\n          -  Pregnant or lactating women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986933", 
            "org_study_id": "CIM003JG"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group1", 
                    "Group2", 
                    "Group3", 
                    "Group4", 
                    "Group5"
                ], 
                "intervention_name": "CIM331", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group5", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anniston", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36207"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington Heights", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60005"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46256"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28226"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29407"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37215"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "College Station", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77845"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23507"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY", 
        "overall_contact": {
            "email": "cim331@chugai-pharm.co.jp", 
            "last_name": "Clinical Trials Administrator"
        }, 
        "overall_official": {
            "affiliation": "Chugai Pharmaceutical", 
            "last_name": "Michiaki Tanaka", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Japan: Ministry of Health, Labor and Welfare", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Germany: Paul-Ehrlich-Institu", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percent improvement from baseline in pruritus VAS at week12", 
            "measure": "Percent improvement from baseline in pruritus Visual Analogue Scale (VAS)", 
            "safety_issue": "No", 
            "time_frame": "baseline to week12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986933"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Improvement from baseline in Eczema Area and Severity Index (EASI)", 
                "safety_issue": "No", 
                "time_frame": "baseline to week12 (Part A), up to week64 (Part B)"
            }, 
            {
                "measure": "Improvement from baseline in SCORing Atopic Dermatitis (SCORAD)", 
                "safety_issue": "No", 
                "time_frame": "baseline to week12 (Part A), up to week64 (Part B)"
            }, 
            {
                "measure": "Improvement from baseline in static Investigator's Global Assessment (sIGA)", 
                "safety_issue": "No", 
                "time_frame": "baseline to week12 (Part A), up to week64 (Part B)"
            }, 
            {
                "measure": "Improvement from baseline in Body Surface Area (BSA) of AD involvement", 
                "safety_issue": "No", 
                "time_frame": "baseline to week12 (Part A), up to week64 (Part B)"
            }
        ], 
        "source": "Chugai Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chugai Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}